Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Akeso, Inc. ( (HK:9926) ).
Akeso, Inc. announced that its bi-specific antibody, ivonescimab, has received approval from the National Medical Products Administration for its use as a first-line treatment for non-small cell lung cancer (NSCLC) with positive PD-L1 expression. This approval is based on successful Phase III trial results demonstrating ivonescimab’s efficacy over pembrolizumab, marking a significant advancement in chemotherapy-free treatment options for NSCLC, and potentially enhancing Akeso’s position in the oncology market.
More about Akeso, Inc.
Akeso, Inc. is a biopharmaceutical company focused on developing innovative immuno-therapy drugs. The company specializes in creating bi-specific antibodies, with a market focus on treating various cancers including lung, biliary tract, and breast cancer.
YTD Price Performance: 62.93%
Average Trading Volume: 13,490,317
Technical Sentiment Signal: Sell
Current Market Cap: HK$88.77B
See more insights into 9926 stock on TipRanks’ Stock Analysis page.